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A B S T R A C T
Sirtuins (SIRT1–SIRT7) are an evolutionary conserved family of NAD+-dependent protein deacylases regulating
the acylation state of ε-N-lysine residues of proteins thereby controlling key biological processes. Numerous
studies have found association of the aberrant enzymatic activity of SIRTs with various diseases like diabetes,
cancer and neurodegenerative disorders. Previously, we have shown that substituted 2-alkyl-chroman-4-one/
chromone derivatives can serve as selective inhibitors of SIRT2 possessing an antiproliferative effect in two
human cancer cell lines. In this study, we have explored the bioisosteric replacement of the chroman-4-one/
chromone core structure with different less lipophilic bicyclic scaffolds to overcome problems associated to poor
physiochemical properties due to a highly lipophilic substitution pattern required for achieve a good inhibitory
effect. Various new derivatives based on the quinolin-4(1H)-one scaffold, bicyclic secondary sulfonamides or
saccharins were synthesized and evaluated for their SIRT inhibitory effect. Among the evaluated scaffolds, the
benzothiadiazine-1,1-dioxide-based compounds showed the highest SIRT2 inhibitory activity. Molecular mod-
eling studies gave insight into the binding mode of the new scaffold-replacement analogues.
1. Introduction
Bioisosterism is a common strategy for optimization of lead com-
pounds in medicinal chemistry which involves structural modifications
of bioactive compounds by replacement of functional groups or scaf-
folds. We have used the chromone and chroman-4-one ring systems as
scaffolds for the development of potent and selective sirtuin 2 (SIRT2)
enzyme inhibitors (Fig. 1).1,2 Sirtuins (SIRTs) catalyze the deacylation
of lysine residues on numerous protein substrates requiring NAD+ as a
co-substrate.3,4 The SIRT enzymes are considered to be important in
various pathologies such as cancer, neurodegeneration, diabetes, in-
flammation and cardiovascular diseases and therefore, the development
of SIRT inhibitor is of vast interest.5–10 Despite the synthetic efforts to
develop potent inhibitors the majority of the reported inhibitors show
IC50 values in the submicromolar to micromolar range with only a
handful of examples exibiting nanolar inhibitory activity.9,11
A drawback of the previously described chromone and chroman-4-
one based SIRT2 inhibitors (e.g. 1, Fig. 1)1 was their high lipophilicity
which prevented their use in more advanced biological assays as they
precipitated at relevant test concentrations. Efforts to increase the hy-
drophilicity afforded compounds containing heterofunctional groups
such as pyridyl or oxadiazole moieties (3 and 5, respectively, Fig. 1)
that allowed them to be tested for their SIRT2-mediated anti-
proliferative effects in cancer cells.2
To further improve the physicochemical properties of potential
SIRT2 inhibitors we decided to investigate the effect of replacing the
chroman-4-one scaffold with other heterocyclic frameworks (Scheme
1).
In the present study, a set of compounds based on three types of
bicyclic scaffolds has been synthesized and evaluated for their activity
as sirtuin inhibitors.
Quinolin-4(1H)-ones (A) and bicyclic secondary sulfonamides such
as benzothiazine-1,1-dioxides (B) and benzothiadiazine-1,1-dioxides
(C–D), or saccharins (E) are versatile scaffolds found in bioactive
compounds. The quinolin-4(1H)-one is structurally similar to the
chromone and is a common scaffold in antibacterial agents such as
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fluoroquinolones.12 Benzothiadiazine-1,1-dioxide derivatives have
been used as diuretic drugs since the 1950s and this scaffold is a fre-
quent motif also in other biologically relevant substances.13,14 Sac-
charin, widely used as an artificial sweetener, has been successfully
used as a core structure in e.g. inhibitors of carbonic anhydrases15 and
is also a key element of repinotan, a highly selective 5-HT1A-receptor
agonist.16 The new scaffold analogues contained comparable substitu-
tion patterns to the previously studied chroman-4-ones/chromones. The
observed structure-activity relationships (SAR) were in agreement with
the findings from docking studies conducted with a SIRT2 3D model
previously published.2
2. Results and discussion
2.1. Design
The design of new scaffold analogues was guided by SAR studies
and the suggested binding mode achieved from molecular modelling
trials performed around the parent chroman-4-one/chromone scaf-
fold.1,2 The main focus was the replacement of the core structure with
less lipophilic ring systems in order to improve the physicochemical
properties. To elucidate the influence of the scaffold replacement on the
inhibitory properties, we aimed to retain a characteristic substitution
pattern which has proven to be vital for inhibitory activity of deriva-
tives based on the chroman-4-one/chromone framework. Hence, the
scaffolds should contain a hydrogen bond acceptor (HBA) group mi-
micking the carbonyl group thereby retaining the hydrogen bond to a
structural water molecule. In addition, the introduction of functional
groups in positions mimicking the 2- and 6-position of the chroman-4-
ones/chromones should be allowed (see Scheme 1 for numbering). The
new compounds should preferably be brominated at the site corre-
sponding to the 6-position of the parent scaffold since chroman-4-one
derivatives holding a Br-substituent in this position showed higher in-
hibitory activity than other substituents due to a halogen bond inter-
action with a backbone carbonyl group of SIRT2. Introduction of an
additional Br-group in the corresponding 8-position might be beneficial
to increase the inhibitory activity even further due to hydrophobic in-
teractions with the target protein. The substituent in the 2-position of
the chroman-4-ones/chromones is located in a narrow hydrophobic
tunnel pointing towards the surrounding water environment. Conse-
quently, the group representing this substituent should be a linear ali-
phatic moiety which can be substituted with heterocycles and bulkier
groups when separated from the core structure with at least an ethylene
spacer.1,2
The heterocyclic frameworks shown in Scheme 1 emerged as pro-
mising alternatives as they are similar in size to the chroman-4-ones/
chromones, readily accessible by synthesis and can be substituted with
functional groups in equivalent positions as the parent scaffold to
maintain the key binding properties of known, potent SIRT2-selective
inhibitors (Fig. 1, 1–5). The calculated logP values of scaffolds B–E are
significantly lower than the one of the chroman-4-one scaffold, in-
dicating a good starting point for addressing the issues of the less fa-
vourable physicochemical properties exhibited by the chroman-4-one
series. In addition, the quinolin-4-(1H)-one framework (A) was also
considered to be of interest due to its structural similarities to the
chromone scaffold despite its higher clogP-value.
2.2. Chemistry
The synthesis towards the quinolin-4-(1H)-one-based analogues is
shown in Scheme 2. The scaffold was synthesized from β-ketoesters and
anilines employing the Conrad-Limpach reaction. The β-ketoesters 8a–c
were obtained in good yields by reacting monomethyl potassium mal-
onate (6) with the CDI-activated carboxylic acids 7a–c in anhydrous
THF at room temperature.17 2-Bromo-4-chloroaniline was then reacted
with 8a–c under argon at 50 °C for 48 h to afford the intermediate
enaminoesters 9a–c. After removal of excess aniline and p-toluene-
sulfonic acid (p-TSA) the cyclization was achieved by heating the en-
aminoesters to 250 °C in diphenyl ether for 45 min using microwave
heating. The quinolin-4-(1H)-ones 10a–c were finally isolated by
crystallization from hexane.
Four analogues with the benzothiazine-1,1-dioxide scaffold were
Fig. 1. SIRT2 selective chroman-4-one based inhibitors. (%-Inhibition at 200 µM inhibitor conc.)
Scheme 1. Overview over the scaffolds en-
visioned to replace the chroman-4-one fra-
mework in the SIRT2 inhibitors. Apart from
Scaffold A, the new bicyclic ring systems
show lower lipophilicity than the chroman-
4-one scaffold as reflected by the calculated
logP values (logP values are calculated of
the unsubstituted scaffolds (R = R′ = H)).
The key-binding interactions of the
chroman-4-one based inhibitors with SIRT2
have been highlighted in 2.2
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synthesized as outlined in Scheme 3. 2-Aminobenzenesulfonamide (11)
was reacted in a Sandmeyer-type reaction with NaNO2 at 0 °C followed
by the addition of KI. Introduction of the bromide in the 5-position was
pursued via the reaction of 12 with N-bromosuccinimide (NBS). Aryl
iodides 12 and 13 were successfully used in a Sonogashira reaction
yielding the precursor for the subsequent 6-endo-dig cyclization to af-
ford the desired products 15a–d.
The synthesis of derivatives based on the benzothiadiazine-1,1-di-
oxide scaffolds is shown in Scheme 4. 2-Amino-3,5-di-
bromobenzenesulfonamide 11 was obtained by reacting 2-amino-
benzene-sulfonamide with Br2 in DMF at room temperature.
Sulfonamide 16 was then either reacted with various aldehydes or
carboxylic acids which defined the substituent in the 3-position and the
degree of saturation of the scaffold. Aldehydes 17a and 17b employed
in the aforementioned reaction were commercially available. Whereas,
compound 17c was obtained via a reduction-oxidation protocol from 3-
(3-bromophenyl)propionic acid (Supporting Information) and 17d,
used to introduce the quinolin-2(1H)-one moiety in the 3-position of
18d, was synthesized in three steps as previously reported by our
group.2 The acid-catalyzed reaction of 16 with aldehydes 17a–d was
carried out under microwave heating at 120 °C in dioxane to afford
18a–d in 34–53% yield.
As outlined in Scheme 4, the unsaturated benzothiadiazine-1,1-di-
oxides 21a–c were synthesized via a reaction of CDI-activated car-
boxylic acids with 16 leading to amide intermediates 20a–c which were
cyclized under microwave heating to afford 21a–c.18
The synthesis of saccharin derivatives substituted in the 2-position
is shown in Scheme 5. As earlier mentioned the SAR study of the
chroman-4-ones revealed that halogen atoms in the 6- and 8-positions
are essential for activity. Thus, dibrominated saccharins were con-
sidered promising derivatives. However, bromination of 2-methylben-
zenesulfonamide by the previously used method (Br2 in DMF) was
unsuccessful. Attempts to obtain a dihalogenated precursor for sac-
charin synthesis via chlorosulfonation of 4-bromo-2-chlorotoluene
yielded only the non-desired isomer, with the sulfonyl chloride moiety
in the meta-position to the methyl group.
Instead, the mono-brominated derivative 23 was synthesized by
chlorosulfonation of 4-bromotoluene (22). The desired isomer 23 was
obtained together with small amounts of the meta-substituted regioi-
somer (14–21%). The isomeric mixture was used in the following re-
action converting 23 to the corresponding sulfonamide 24 with aqu-
eous ammonia. A subsequent oxidation reaction, as reported by Xu et al.
using H5IO6 and sub-stoichiometric amounts of CrO3 furnished 6-bro-
mosaccharin (28) in 46% yield.19 Alternatively, 28 was obtained in
Scheme 2. Synthesis of quinolin-4-(1H)-one derivative 10a–c. Reagents and conditions: (a) CDI, MgCl2, THF, room temp, 16 h, 74–78%; (b) 2-bromo-4-chlor-
oaniline, p-TSA, neat, 50 °C, 48 h; (c) i. cyclohexane, reflux, 30 min; ii. Ph2O, 250 °C, 45 min, MW, 24–26% over two steps from 8a–c.
Scheme 3. Synthesis of 2H-benzo[e][1,2]thiazine-1,1-dioxide 15a–d. Reagents and conditions: (a) i. NaNO2, H2O:HCl (6:4), 0 °C, 40 min; ii. KI, 90 °C, 5 h, 63%; (b)
NBS, conc. H2SO4, 60 °C, 24 h; 87%; (c) 12 or 13, Pd(PPh3)2Cl2, CuI, Et3N, appropriate alkyne, DMF, room temp, overnight, 64–77%; (d) Pd(PPh3)2(OAc)2, KOH,
DMF, 60 °C, 4.5–5 h, 25–46%.
Scheme 4. Synthesis of the saturated and unsaturated benzothiadiazine-1,1-dioxides 18a–d and 21a–c. Reagents and conditions: (a) Br2, DMF, 10 °C → room temp,
22 h, 99% crude yield; (b) appropriate aldehyde, 4 M HCl in dioxane, 120 °C, MW, 1–2.5 h, 34–53%; (c) i. appropriate carboxylic acid, CDI, CH2Cl2, room temp, 1.5 h;
ii. 16, CH2Cl2, DMF, reflux, 21 h; (d) Cs2CO3, EtOH, 120 °C, 1.5 h, MW, 21–37% over two steps.
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62% overall yield via oxidative cyclization under similar conditions of
N-tert-butyl sulfonamide 27 followed by removal of the tert-butyl group
in refluxing trifluoroacetic acid (TFA). However, the final deprotection
step of 26 proceeds very slowly on larger scale and is therefore time
consuming.
Finally, commercially available saccharin 27 and 6-bromosaccharin
28 were converted to their corresponding sodium salts using NaOMe in
MeOH and were further subjected to an alkylation with a variety of
alkyl halides containing different terminal heterofunctionalities and
aryl groups (31a–d, 32a–f).
2.3. Physicochemical evaluation
In this study we attained scaffold analogues with an improved
physicochemical profile (Supporting Information, Table S1). The com-
puted physicochemical properties (molecular weight, clogP, PSA, HBD,
HBA) of the new derivatives conformed with Lipinski’s rule of five.
Even though we maintained the highly lipophilic substitution pattern
required to assure a minor loss in inhibitory activity1,2 a clear im-
provement in polarity can be seen in the increase in PSA and the
number of HBD and HBA. Derivatives based on the bicyclic sulfona-
mides (B–D) and saccharins (E) showed at a least twofold increase in
PSA and a decrease by one unit in clogP compared to active chroman-4-
one based derivatives (e.g. 1–3).
2.4. Biological evaluation
The synthesized compounds were evaluated in a fluorescence-based
assay for their inhibitory activity against SIRT2 at a compound con-
centration of 200 µM.2,20 The most active derivatives from each scaffold
class were also tested for their inhibitory effect on SIRT1 and SIRT3 to
investigate their selectivity towards the SIRT2-isoform. The results are
summarized in Tables 1–3.
The quinolone-4-(1H)-one series (Table 1) resembles chromone in
which the oxygen in the 1-position is replaced with a hydrogen bond
donating NH-group. The evaluation of the inhibitory effect towards
SIRT2 showed that similar biological effects cannot be achieved in this
series despite its structural similarity to the chromone scaffold
(Table 1).
Further, as summarized in Table 2, we tested various analogues
based on bicyclic sulfonamide scaffolds B–D substituted with aliphatic
groups (butyl, pentyl, phenethyl) in the 3-position as well as the bulkier
2-quinolinone group (18d). The mono-brominated bicyclic sulfona-
mides 15c and 15d based on scaffold B (Table 2) displayed only poor
inhibitory activity with the phenethyl derivative 15d being the most
active (35% inhibition at 200 µM concentration). Compared to non-
brominated 15a and b, introduction of the Br-group had only a mar-
ginal effect on the inhibitory activity as compared to the corresponding
effect among the chroman-4-ones.1
The di-brominated derivatives 18a–d based on the saturated bi-
cyclic sulfonamide core structure C showed increased activity
Scheme 5. Synthesis of saccharin derivatives. Reagents and conditions: (a) ClSO3H, CH2Cl2, 0 °C → room temp, overnight, 81%; (b) NH4OH, Et2O, 0 °C → reflux →
room temp, 48 h, 74%; (c) H5IO6, CrO3, MeCN, reflux, 20 h, 38%; (d) tert-BuNH2, Et3N, Et2O, 0 °C → room temp, 33 h, 81%; (e) H5IO6, CrO3, Ac2O, MeCN, 0 °C →
room temp, 20 h; (f) TFA, reflux → room temp, 4 d, 51% over three steps (d–f); (g) NaOMe, MeOH, 6 h, room temp,> 99%; (h) Alkyl halide, DMF, MW, 145 °C,
15 min. or 1 h, 12–79%.
Table 1
SIRT2 inhibitory activities of quinolin-4-(1H)-one derivatives 10a–c. For se-
lected analogues inhibition of SIRT1 and SIRT3 was investigated as well.a,b,c.
No. R2 Inhibition (%)a,b,c
SIRT1 SIRT2 SIRT3
33 9.8 ± 2.8 82 ± 0.4 4.5 ± 1.6
34 n.d. 75 ± 2.6 n.d.
10a n.d. 26 ± 1.4 n.d.
10b 7.6 ± 2.2 58 ± 2.1 41 ± 3.0
10c n.d. 53 ± 1.1 n.d.
a SD, standard deviation (n = 3).
b Inhibition at 200 µM inhibitor concentration.
c n.d. = not determined.
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compared to 15c–d. Compound 18d was the most potent compound of
the benzothiadiazine-1,1-dioxides with 74% inhibition of SIRT2. The
unsaturated analogues 21a–c were considerably less potent (10–24%
inhibition) with inhibitory activities in the range with the non-halo-
genated analogues based on scaffold B. Moreover, 21a–c showed very
low solubility in most solvents and were therefore not considered for
future optimization.
The last scaffold evaluated in the study was the saccharin core, i.e.
compounds 31a–d and 32a–f. As shown in Table 3, derivatives based
on this core structure showed only a minimal inhibitory effect, 31a and
31b as most active showed 34% at 200 µM concentration. For this
series, the introduction of a bromide in the aromatic ring (32a–f) did
not improve the activity.
2.5. Structure-activity relationship and molecular modeling
In order to investigate and get a better understanding of the ob-
served SAR among these new series of compounds molecular modeling
and docking studies were performed. For the docking trials we used our
3D model of SIRT2 which was previously used for docking studies of the
corresponding chromones and chroman-4-ones.2 The docking was
performed using Glide with the OPLS3 force field21 as implemented in
the Schrödinger software.22 OPLS3 is superior in predicting pro-
tein–ligand binding energy to commonly used force fields (e.g.
OPLS_2005 and MMFF)23,24 and it is also parametrized to predict the
geometry and energy contribution of aryl halogen bonds more accu-
rately.25 In the docking procedure the SIRT2 3D-structure was kept
rigid while the ligands were flexible. A representative compound from
each scaffold series was included together with a set of relevant pre-
viously published structurally analogous chroman-4-ones as reference
ligands. Docking scores obtained from representative compounds of
each compound class were compared (Supporting Information, Table
S2). The rank of the docking scores was in good agreement with the
decreasing inhibitory activity from the most potent chroman-4-one (3)
to the saccharins comprising the least active series of the new analo-
gues.
As illustrated in Fig. 2, docking studies of quinolone-4-(1H)-one 10b
revealed a similar binding mode as observed for the chroman-4-ones/
chromones with the presence of the key enzyme/inhibitor interactions
(see Fig. 1) such as the halogen bond and the hydrogen bond-interac-
tion as well as the π-π interactions. However, in the suggested binding
mode of this scaffold the polar NH-group of the quinolone-4-(1H)-ones
is unfavourably positioned in a hydrophobic region close to Leu103 and
138 (Fig. 2). This in turn, might explain the decrease in inhibitory
Table 2
SIRT2 inhibitory activities of benzothiazine-1,1-dioxide 15a–d and benzothia-
diazine-1,1-dioxides 18a–d and 21a–c. For selected analogues inhibition of
SIRT1 and SIRT3 was also investigated.a,b,c
No. Scaffold R3 Inhibition (%)a,b,c
SIRT1 SIRT2 SIRT3
15a B n.d. 12 ± 2.3 n.d.
15b B n.d. 15 ± 6.5 n.d.
15c B n.d. 29 ± 4.1 n.d.
15d B n.d. 35 ± 1.7 n.d.
18a C 4.4 ± 2.8 32 ± 2.2 5.8 ± 3.4
18b C 4.6 ± 4.2 47 ± 1.9 54 ± 9.2
18c C 9.7 ± 3.9 59 ± 0.4 9.9 ± 1.5
18d C 25 ± 1.6 74 ± 1.3 28 ± 1.5
21a D n.d. 15 ± 3.1 n.d.
21b D 0 ± 3.7 24 ± 0.8 3.2 ± 2.0
21c D n.d. 10 ± 1.5 n.d.
a SD, standard deviation (n = 3).
b Inhibition at 200 µM inhibitor concentration.
c n.d. = not determined.
Table 3
SIRT2 inhibitory activities of saccharin derivatives 31a–d and 32a–f. For se-
lected analogues inhibition of SIRT1 and SIRT3 was also investigated.a,b,c
No. R6 R2 Inhibition (%)a,b,c
SIRT1 SIRT2 SIRT3
31a H n.d. 34 ± 2.5 n.d.
31b H 14 ± 6.3 34 ± 2.8 14 ± 2.8
31c H 8.7 ± 3.4 13 ± 5.0 7.2 ± 1.9
31d H 17 ± 4.3 12 ± 4.9 14 ± 2.4
32a Br n.d. 6.9 ± 2.6 n.d.
32b Br 3.8 ± 4.3 4.7 ± 3.5 1.6 ± 2.2
32c Br 5.2 ± 4.0 12 ± 4.8 15 ± 5.6
32d Br n.d. 15 ± 1.9 n.d.
33e Br n.d. 6.2 ± 4.2 n.d.
32f Br n.d. 13 ± 4.4 n.d.
a SD, standard deviation (n = 3).
b Inhibition at 200 µM inhibitor concentration.
c n.d. = not determined.
Phe96
His187
Leu138
Leu103
Pro94
Gln167
Asn168
Asp170
Ile93
W1
Fig. 2. Quinolone-4-(1H)-one analogue 10b docked in the C-pocket of SIRT2.
The key enzyme/inhibitor interactions are present, i.e. the halogen bond to
His187, the hydrogen bond to W1, and the π-π interaction to Phe96. The NH
moiety in 10b is positioned in a hydrophobic region, close to two leucine re-
sidues (Leu103 and Leu138). The hydrophilic (purple) and hydrophobic (green)
regions are highlighted on the surface of the binding site. (For interpretation of
the references to colour in this figure legend, the reader is referred to the web
version of this article.)
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activity.
The docking trial of the bicyclic sulfonamide scaffolds B–D revealed
that they adopt similar binding poses as that observed for the parent
scaffold. When looking at the binding pose of 15d and 18d as re-
presentative structures (Fig. 3A and B) in the SIRT2 homology model,
the Br-group in the 7-position (corresponding to 6-position of the
chroman-4-ones) forms the expected halogen-bond with a backbone
carbonyl group of SIRT2. The other Br-group of the dibrominated de-
rivatives (Fig. 3B) is buried in the hydrophobic pocket. The SO2NH-
group is placed in close proximity of a hydrogen bonding network
comprising Ser88, His149, Thr166, Asn168, Asp170, Glu173 and a
structural water molecule (W2) (see Fig. 3A), this network is highly
conserved throughout the sirtuin family. The sulfonyl interacts with the
protein via a hydrogen bond of one of the sulfonyl oxygens with W1,
while the second oxygen is positioned in close proximity to Asp170
(3.9 Å) as shown in Fig. 3A and B. This results in an electrostatic re-
pulsion as the side-chain conformation of the aspartate is rotationally
restricted due to its participation in the conserved hydrogen bonding
network. The distance between the sulfonyl oxygen atom and Asp170
(3.9 Å) is also considerably shorter as compared to that between the
carbonyl oxygen of 2 and Asp170 (5.5 Å, Fig. 3C). The electrostatic
repulsion could be the main contributor to the overall decreased in-
hibitory activity observed for scaffolds B–D as compared to the
chroman-4-ones/chromones. In addition, a certain degree of flexibility
in the scaffold might be required for reasonable binding to SIRT2 since
derivatives 21a–c that are based on the more rigid scaffold D only
showed negligible activity.
In general, derivatives based on the saccharin scaffold compose a
series of only weak SIRT2 inhibitors with 34% inhibitory activity as the
best (31a–b). Docking studies of this compound class revealed that they
can adopt two different binding poses with either the sulfonyl group
(Fig. 4A) or the carbonyl moiety (Fig. 4B) interacting with the struc-
tural water (W1) thereby mimicking the carbonyl group of the
chroman-4-ones. Depending on the nature of the hydrogen bond in-
teracting group, the mono-brominated compounds can additionally,
either form the halogen bond (Fig. 4A) or the π-π-interaction with
Phe96 (Fig. 4B).
In this series we observed an opposite trend in the inhibitory effect
where the lack of the halogen substituents slightly increased the ac-
tivity. The non-halogenated saccharin derivatives can bind closer to
His187 thereby increasing the distance between the sulfonyl oxygen to
the acidic Asp170 (4.8 Å). At the same time the carbonyl group is po-
sitioned further away from the lipophilic leucine residues Leu103 and
Leu138 which could result in a more favourable binding mode which
could explain the slight increase in inhibitory activity.
3. Conclusion
We have shown that bicyclic sulfonamides can act as scaffolds for
SIRT inhibitors. The new scaffold analogues comprised a set of pro-
mising SIRT2 inhibitors (50–75% inhibition at 200 µM) with 18d, based
on the sulfonamide scaffold C substituted with a 2-quinolinone con-
taining alkyl group (Table 2), being the most potent inhibitor identified
in our study. Further optimization guided by molecular modeling will
be performed around the benzothiadiazine-1,1-dioxides, to identify
compounds that can be expected to be more potent.
Interestingly, two compounds (10b and 18b) show higher activity
against SIRT3 than what we have previously seen for the chroman-4-
ones. This could be a potential starting point for the development of
either more general SIRT inhibitors, so called pan inhibitors, or of more
SIRT3 selective compounds.
4. Experimental
4.1. General information
All reactions were carried out using magnetic stirring under ambient
atmosphere if not otherwise stated. Room temperature corresponds to a
temperature interval from 20 to 22 °C. All starting materials and re-
agents were obtained from commercial producers and were used
without prior purification. Solvents were generally used as supplied by
the manufacturer. Microwave reactions were carried out using a
Biotage Initiator™ with fixed hold time modus in 0.5–2 mL, 2–5 mL or
10–20 mL capped microwave vials. All reactions were monitored by
thin-layer chromatography (TLC) on silica plated aluminum sheets
(Silica gel 60 F254, E. Merck). Spots were detected by UV light (254 or
365 nm). Purification by flash column chromatography was performed
using an automatic Biotage SP4 Flash+® instrument. Prefabricated
columns of different cartridge sizes (surface area 500 m2/g, porosity
60 Å, particle size 40–63 μm) were used. The NMR spectra were mea-
sured on a Varian 400-MR spectrometer or a 300 MHz instrument. 1H
and 13C NMR spectra were measured at 400 MHz and 100 MHz, re-
spectively. Chemical shifts are reported in ppm with the solvent re-
sidual peak as internal standard [CHCl3 δH 7.26, CDCl3 δC 77.16;
CD2HOD δH 3.31, CD3OD δC 49.00; acetone‑d6 δH 2.05, δC 29.84;
DMSO‑d6 δH 2.50, δC 39.52]. All NMR experiments were measured at
ambient temperature. If not otherwise stated the NMR experiments
were run in CDCl3 at 400 MHz. Combustion analyses for CHN were
measured on a Thermo Quest CE Instruments EA 1110 CHNS-O ele-
mental analyzer or Perkin Elmer 2400 Series II CHNS/O system ele-
mental analyzer. High-resolution mass spectrometry (HRMS) analysis
was obtained from Recipharm OT Chemistry AB, Uppsala (Sweden).
4.2. General procedure for the synthesis of β-ketoesters 8a–c
The carboxylic acid (1 equiv) and CDI (1.1 equiv) were dissolved in
anhydrous THF (0.5 M) and stirred at room temperature for 1 h.
Monomethyl potassium malonate 6 (1.2 equiv) and anhydrous MgCl2
His187
Leu138
Leu103
Pro94
Gln167
Asn168
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Fig. 3. (A) Binding pose of 15d and the observed conserved hydrogen-bond network formed by Ser88, His149, Asp170, Asn168, Glu173 and a structural water
molecule (W2). (B) Docking solution of 18d. (C) The docking pose of the chroman-4-one analogue 2. The carbonyl oxygen is interacting with the structural water
molecule W1 and the distance to Asp170 is 5.5 Å. The hydrophilic (purple) and hydrophobic (green) regions are highlighted in on the molecular surface of the
binding site.
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(1.5 equiv) were added and the reaction was stirred at room tempera-
ture overnight. The reaction was treated with 1 M HCl (aq). The phases
were separated and the aqueous phase was extracted with EtOAc. The
combined organic phases were washed with water and brine, dried over
Na2SO4, filtered and concentrated under reduced pressure. Purification
by flash column chromatography (2 → 22% EtOAc in pentane) afforded
β-ketoesters 8a–c. All 1H NMR spectra also showed trace amounts of the
enol tautomer of the product.
Methyl 3-oxooctanoate (8a). The compound was synthesized ac-
cording to the general procedure from 7a (1.39 g, 12.0 mmol) to afford
8a (1.53 g, 74%) as a colourless oil. 1H NMR (300 MHz) δ 3.73 (s, 3H),
3.45 (s, 2H), 2.53 (t, J= 7.4 Hz, 2H), 1.66–1.54 (m, 2H), 1.38–1.22 (m,
4H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (75 MHz) δ 202.8, 167.7, 52.3,
49.0, 43.0, 31.2, 23.2, 22.4, 13.9.
Methyl 3-oxo-4-phenylbutanoate (8b). The compound was syn-
thesized according to the general procedure from 7b (1.04 g,
7.63 mmol) to afford 8b as a colourless oil (1.30 g, 88%). 1H NMR
(300 MHz) δ 7.37–7.13 (m, 5H), 3.80 (s, 2H), 3.68 (s, 3H), 3.44 (s, 2H).
13C NMR (75 MHz) δ 200.3, 167.5, 133.3, 129.6, 128.9, 127.4, 52.3,
50.0, 48.0.
Methyl 7-methoxycarbonyl-3-oxooctanoate (8c). The compound
was synthesized according to the general procedure from 7c (1.46 g,
13.8 mmol) to afford 8c as a colourless oil (1.51 g, 77%). 1H NMR
(300 MHz) δ 3.74 (s, 3H), 3.67 (s, 3H), 3.45 (s, 2H), 2.57 (t, J= 6.9 Hz,
2H), 2.33 (t, J = 7.1 Hz, 2H), 1.69–1.58 (m, 4H). 13C NMR (75 MHz) δ
202.2, 173.8, 167.6, 52.4, 51.6, 49.0, 42.6, 33.8, 24.3, 22.9.
4.3. General procedure for the synthesis of 4-quinolones 10a–c
β-Ketoester (1 equiv), 2-bromo-4-chloroaniline (1.2 equiv) and p-
TSA (0.1 equiv) were stirred in a sealed reaction vessel at 50 °C for
approximately 48 h. The mixture was transferred to a flask and refluxed
briefly in cyclohexane. The solid was filtered off and the solvent was
evaporated. The residue was dissolved in diphenyl ether (5 mL) and the
solution was heated in a microwave reactor at 250 °C for 45 min. Excess
hexane was added and the product was collected the next day by fil-
tration. The compounds were recrystallized from chloroform/hexane to
remove traces of diphenyl ether.
8-Bromo-6-chloro-2-pentylquinolin-4(1H)-one (10a). The com-
pound was synthesized according to the general procedure from 8a
(544 mg, 3.87 mmol) to afford 10a (255 mg, 25%) as a brown solid. 1H
NMR (300 MHz) δ 8.28 (d, J = 2.3 Hz, 1H), 8.26 (br s, 1H), 7.78 (d,
J = 2.3 Hz, 1H), 6.18 (s, 1H), 2.67 (t, J = 7.7 Hz, 2H), 1.85–1.66 (m,
2H), 1.46–1.32 (m, 4H), 0.99–0.83 (m, 3H). 13C NMR (75 MHz) δ
177.2, 152.9, 135.8, 134.7, 129.5, 127.0, 125.7, 111.7, 109.7, 34.6,
31.2, 27.9, 22.5, 14.0. Anal. Calcd for C14H15BrClNO: C, 51.17; H, 4.60;
N, 4.26. Found: C, 51.67; H, 4.80; N, 4.21.
2-Benzyl-8-bromo-6-chloroquinolin-4(1H)-one (10b). The com-
pound was synthesized according to the general procedure from 8b
(322 mg, 1.68 mmol) to afford 10b (143 mg, 25%) as a brown solid. 1H
NMR (300 MHz) δ 8.26 (d, J = 2.3 Hz, 1H), 8.20 (s, 1H), 7.72 (d,
J= 2.3 Hz, 1H), 7.49–7.27 (m, 5H), 6.24 (s, 1H), 4.04 (s, 2H). 13C NMR
(75 MHz) δ 177.2, 150.8, 135.7, 134.7, 134.3, 129.72, 129.70, 129.5,
128.4, 126.8, 125.7, 111.9, 110.3, 40.4. Anal. (C16H11BrClNO) C, H, N.
Methyl 5-(8-bromo-6-chloro-quinoline-4(1H)-one-2-yl)pen-
tanoate (10c). The compound was synthesized according to the general
procedure from 8c (248 mg, 1.15 mmol) to afford 10c (129 mg, 30%)
as a light brown solid. 1H NMR (300 MHz) δ 8.41 (s, 1H), 8.27 (d,
J = 2.3 Hz, 1H), 7.79 (d, J = 2.3 Hz, 1H), 6.18 (s, 1H), 3.69 (s, 3H),
2.70 (t, J = 7.2 Hz, 2H), 2.40 (t, J = 6.8 Hz, 2H), 1.90–1.68 (m, 4H).
13C NMR (75 MHz) δ 177.2, 173.7, 152.4, 135.8, 134.8, 129.7, 127.0,
125.7, 111.8, 109.8, 51.8, 34.2, 33.6, 27.8, 24.1. Anal.
(C15H15BrClNO3) C, H, N.
4.4. 2-Iodobenzenesulfonamide (12)
To a suspension of 2-aminobenzenesulfonamide 11 (1.5 g,
8.71 mmol) in H2O/HCl (16:11 mL) cooled to 0 °C was added a solution
of NaNO2 (0.91 g, 13.2 mmol) in H2O (16 mL). The mixture was stirred
until a clear yellow solution was formed. A solution of KI (4.34 g,
26.1 mmol) in H2O (16 mL) was added and the red coloured mixture
was heated to 90 °C for 4 h. The mixture was allowed to cool to room
temperature and the formed solid was filtered off, washed with water
and pentane and dried under vacuum to afford 12 (1.65 g, 63%) as a
light brown solid. 1H NMR (DMSO‑d6) δ 8.11 (dd, J= 7.8, 1.2 Hz, 1H),
8.01 (dd, J = 7.9, 1.5 Hz, 1H), 7.58 (ddd, J = 7.9, 7.4, 1.2 Hz, 1H),
7.49 (s, 2H), 7.27 (ddd, J = 7.4, 1.6 Hz, 1H). 13C NMR (DMSO‑d6) δ
145.9, 142.1, 132.8, 128.3, 92.4.
4.5. 5-Bromo-2-iodobenzenesulfonamide (13)
2-Iodobenzenesulfonamide 12 (846 mg, 2.99 mmol) was suspended
in conc. H2SO4 (20 mL) and warmed to 60 °C. N-Bromosuccinimde
(638 mg, 3.59 mmol) was added in one portion and the mixture was
stirred at 60 °C for 24 h. The mixture was poured on ice and the formed
precipitate was filtered off, washed with water and pentane and dried in
vacuo to afford 13 (941 mg, 87%) as off-white solid. 1H NMR
(DMSO‑d6) δ 8.08 (d, J = 2.3 Hz, 1H), 8.03 (d, J = 8.3 Hz, 1H), 7.67
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Fig. 4. (A). Binding pose of 32b which is similar to that of the sulfonamides in where the sulfonyl group interacts with W1 and also forms a halogen bond with the
backbone carbonyl moiety of His187. (B) The alternative pose of 32b rotated 180° in which the hydrogen bond interaction with W1 is maintained via the carbonyl
oxygen. However, this binding prevents any potential halogen bonding with His187. (C) Binding pose of the non-halogenated saccharin analogue 31b which interacts
with the structural water W1 and places the sulfonyl and carbonyl group further away from the acidic Asp170 (4.8 Å) and Leu103 and Leu138. However, the distance
between the aromatic ring in the ligand and Phe96 is longer which weakens the π-π-interaction. The hydrophilic (purple) and hydrophobic (green) regions are
highlighted in on the molecular surface of the binding site. (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
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(br s, 2H), 7.49 (dd, J= 8.3, 2.3 Hz, 1H). 13C NMR (DMSO‑d6) δ 147.8,
144.0, 135.5, 130.6, 121.4, 91.3.
4.6. General procedure for synthesis of alkyne derivatives 14a–c
To a vial with the appropriate 2-iodobenzenesulfonamide (1 equiv),
Pd(PPh3)2Cl2 (0.1 equiv) and CuI (0.1 equiv) was added DMF (0.2 M)
and Et3N (10 equiv) and the mixture was purged with N2 gas. The
appropriate alkyne (1.5 equiv) was added and the reaction mixture was
stirred at room temperature overnight. The mixture was diluted with
EtOAc and filtered through Celite™. The organic phase was washed with
0.1 M HCl, water (3 × ) and brine (2 × ), dried over MgSO4, filtered
and concentrated under reduced pressure. The crude product was
purified by automated flash column chromatography (15%→20%
EtOAc/pentane) to afford the desired products.
2-(Hex-1-yn-1-yl)benzenesulfonamide (14a) The compound was
synthesized according to the general procedure from 12 (400 mg,
1.40 mmol), Purification by automated flash column chromatography
(0 → 45% EtOAc/pentane) to afford 14a (224 mg, 67%) as a white
solid. 1H NMR δ 8.07 (d, J = 2.0 Hz, 1H), 7.58 (dd, J = 8.2, 2.1 Hz,
1H), 7.40 (d, J = 8.2 Hz, 1H), 5.36 (s, 3H), 2.50 (t, J = 7.2 Hz, 2H),
1.69–1.56 (m, 2H), 1.54–1.40 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H). 13C
NMR δ 142.7, 134.3, 131.9, 127.6, 126.8, 121.1, 100.2, 77.4, 30.3,
22.0, 19.3, 13.5.
2-(4-Phenylbut-1-yn-1-yl)benzenesulfonamide (14b) The com-
pound was synthesized according to the general procedure from 12
(400 mg, 1.40 mmol), Purification by automated flash column chro-
matography (0 → 45% EtOAc/pentane) to afford 14b (309 mg, 77%) as
a yellow solid. 1H NMR δ 7.92 (dd, J = 7.9, 1.3 Hz, 1H), 7.51 (dd,
J= 7.6, 1.4 Hz, 1H), 7.45 (td, J= 7.5, 1.4 Hz, 1H), 7.39–7.19 (m, 6H),
4.77 (br s, 1H), 2.96 (td, J= 7.0, 1.3 Hz, 2H), 2.86 (td, J= 6.8, 1.3 Hz,
2H). 13C NMR δ 143.2, 140.1, 134.5, 132.1, 128.8, 128.7, 128.0, 127.2,
126.8, 121.0, 99.0, 78.4, 34.3, 21.7.
5-Bromo-2-(hex-1-yn-1-yl)benzenesulfonamide (14c) The com-
pound was synthesized according to the general procedure from 13
(108 mg, 0.30 mmol), Purification by automated flash column chro-
matography (0 → 30% EtOAc/pentane) to afford 14c (60 mg, 64%) as
an off-white solid. 1H NMR δ 8.11 (d, J = 2.0 Hz, 1H), 7.60 (dd,
J = 8.2, 2.1 Hz, 1H), 7.41 (d, J = 8.2 Hz, 1H), 5.27 (s, 2H), 2.51 (t,
J = 7.2 Hz, 2H), 1.69–1.58 (m, 2H), 1.54–1.41 (m, 2H), 0.95 (t,
J = 7.3 Hz, 3H). 13C NMR δ 144.3, 135.7, 135.2, 130.2, 121.8, 120.2,
101.7, 76.9, 30.4, 22.2, 19.6, 13.7.
5-Bromo-2-(4-phenylbut-1-yn-1-yl)benzenesulfonamide (14d)
The compound was synthesized according to the general procedure
from 13 (105 mg, 0.29 mmol), Purification by automated flash column
chromatography (0 → 40% EtOAc/pentane) to afford 14d (68 mg,
65%) as an off-white solid. 1H NMR δ 8.03 (d, J = 2.0 Hz, 1H), 7.55
(dd, J= 8.2, 2.1 Hz, 1H), 7.35 (d, J= 8.3 Hz, 1H), 7.34–7.19 (m, 5H),
4.79 (s, 3H), 2.95 (dd, J = 7.3, 5.8 Hz, 2H), 2.85 (td, J = 6.7, 1.2 Hz,
2H). 13C NMR δ 144.4, 139.9, 135.7, 135.1, 130.1, 128.8, 128.6, 126.9,
121.9, 119.9, 100.2, 77.7, 34.1, 21.7.
4.7. General procedure for synthesis of benzothiazine-1,1-dioxides 15a–d
A solution of the alkyne (1 equiv) in DMF (0.1 M) was added to a
oven-dried MW vial containing KOH (4 equiv) and Pd(PPh3)2OAc2
(0.05 equiv). The mixture was heated to 60 °C for 4.5–5 h. The mixture
was diluted with EtOAc and washed with 1 M HCl (aq.), water and
brine, dried over MgSO4, filtered and concentrated to afford the desire
products after purification by automated flash column chromatography.
3-Butyl-2H-benzo[e][1,2]thiazine 1,1-dioxide (15a) The com-
pound was synthesized according to the general procedure from 14a
(224 mg, 0.94 mmol). Purification by automated flash column chro-
matography (0 → 20% EtOAc/pentane) to afford 15a (95 mg, 42%) as a
colourless oil that crystalizes over time. 1H NMR δ 7.93–7.79 (m, 1H),
7.54 (br s, 1H, NH), 7.53 (ddd, J = 7.9, 7.4, 1.3 Hz, 1H), 7.38 (td,
J = 7.7, 1.2 Hz, 1H), 7.32–7.28 (m, 1H), 6.03 (s, 1H), 2.48–2.33 (m,
2H), 1.62 (ddt, J = 8.7, 7.5, 6.4 Hz, 2H), 1.53–1.28 (m, 2H), 0.93 (t,
J = 7.3 Hz, 3H). 13C NMR δ 141.3, 133.8, 132.2, 130.4, 126.7, 126.6,
121.3, 104.8, 34.4, 29.2, 22.0, 13.9. Anal. (C12H15NO2S) C, H, N.
3-Phenethyl-2H-benzo[e][1,2]thiazine 1,1-dioxide (15b) The
compound was synthesized according to the general procedure from
14b (309 mg, 1.08 mmol). Purification by automated flash column
chromatography (0 → 20% EtOAc/pentane) to afford 15b (110 mg,
36%) as a yellow oil. 1H NMR δ 7.85 (dd, J = 8.0, 1.2 Hz, 1H), 7.80 (s,
1H), 7.50 (td, J = 7.6, 1.3 Hz, 1H), 7.36 (td, J = 7.7, 1.2 Hz, 1H),
7.32–7.15 (m, 6H), 5.97 (s, 1H), 2.95 (dd, J = 8.9, 6.7 Hz, 2H), 2.66
(dd, J= 8.8, 6.8 Hz, 2H). 13C NMR δ 140.3, 140.2, 133.6, 132.2, 130.4,
128.6, 128.6 126.8, 126.7, 126.4, 121.2, 105.3, 36.7, 33.6. Anal.
(C16H15NO2S·0.6 H2O) C, H, N.
7-Bromo-3-butyl-2H-benzo[e][1,2]thiazine 1,1-dioxide (15c) The
compound was synthesized according to the general procedure from
14c (60 mg, 0.19 mmol). Purification by automated flash column
chromatography (0 → 20% EtOAc/pentane) to afford 15c (15 mg, 25%)
as a colourless oil that crystalizes over time. 1H NMR δ 7.97 (d,
J = 2.1 Hz, 1H), 7.64 (dd, J = 8.4, 2.0 Hz, 1H), 7.19 (d, J = 8.4 Hz,
1H), 7.13 (br s, 1H), 6.03 (s, 1H), 2.39 (t, J = 7.6 Hz, 2H), 1.63 (dddd,
J = 8.6, 7.5, 7.0, 5.8 Hz, 2H), 1.47–1.33 (m, 2H), 0.95 (t, J = 7.3 Hz,
3H). 13C NMR δ 141.6, 135.3, 132.6, 131.8, 128.3, 124.2, 119.7, 104.8,
34.6, 29.2, 22.1, 13.9. HRMS (ESI) m/z calcd for C12H15BrNO2S
[M + H]+ 316.0007, found 316.0009.
7-Bromo-3-phenethyl-2H-benzo[e][1,2]thiazine 1,1-dioxide
(15d) The compound was synthesized according to the general proce-
dure from 14c (68 mg, 0.19 mmol). Purification by automated flash
column chromatography (0 → 20% EtOAc/pentane) to afford 15c
(31 mg, 46%) as a colourless oil that crystalizes over time. 1H NMR δ
7.98 (d, J= 2.1 Hz, 1H), 7.64 (dd, J= 8.4, 2.0 Hz, 1H), 7.38–7.19 (m,
5H), 7.16 (d, J = 8.4 Hz, 1H), 6.79 (br s, 1H), 5.99 (s, 1H), 2.97 (t,
J = 7.6 Hz, 1H), 2.69 (t, J = 7.6 Hz, 2H). 13C NMR δ 140.5, 139.8,
135.4, 132.3, 132.0, 128.9, 128.6, 128.5, 126.8, 124.3, 120.1, 105.6,
36.9, 33.7. HRMS (ESI) m/z calcd for C16H15BrNO2S [M+H]+
364.0007, found 364.0011.
4.8. 2-Amino-3,5-dibromobenzenesulfonamide (16)
Br2 (0.75 mL, 15 mmol) was added dropwise to a solution of 2-
aminobenzenesulfonamide 15 (1.01 g, 5.85 mmol) in DMF (4 mL)
at< 10 °C. The dark brown solution was stirred at 10–15 °C for 15 min
and then continued to stir at room temperature for 23 h. Additional Br2
(0.15 mL, 2.9 mmol) was added and the stirring was continued at room
temperature for 22 h. The mixture was diluted with EtOAc and treated
with 10% Na2S2O3 (aq.). After 10 min of stirring water was added, the
phases were separated and the aqueous phase was extracted with
EtOAc. The combined organic phases were washed with sat. Na2CO3
(aq), water and brine, dried over MgSO4, filtered and concentrated
under reduced pressure to afford 16 (1.96 g,> 99%) as a light-brown
solid, which was directly used in the next step. 1H NMR (DMSO‑d6) δ
7.85 (d, J= 2.3 Hz, 1H), 7.71 (d, J= 2.4 Hz, 1H), 7.65 (s, 2H), 6.02 (s,
2H). 13C NMR (DMSO‑d6) δ 141.5, 137.6, 129.7, 127.0, 110.6, 105.1.
4.9. General procedure for synthesis of saturated benzothiadiazine
derivatives 18a–d
Compound 16 (1.1–1.2 equiv) and the appropriate aldehyde 17a–d
(1 equiv) were dissolved in 4 M HCl in dioxane (0.04–0.06 M). The
mixture was heated in a microwave reactor at 120 °C for 1.5 h.
Work-up procedure A. The solvent was removed and the residue
was diluted with EtOAc. The organic phase was washed with 2 M NaOH
(aq), water, 0.1 M HCl (aq), water and brine, dried over MgSO4, filtered
and concentrated under reduced pressure.
Work-up procedure B. The product was isolated by filtration and
washed with EtOAc.
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5,7-Dibromo-3-pentyl-3,4-dihydro-2H-benzo[e][1,2,4]thiadia-
zine-1,1-dioxide (18a). The compound was synthesized according to
the general procedure from 16 (198 mg, 0.60 mmol), hexanal (17a,
0.05 mL, 0.50 mmol) and 4 M HCl in dioxane (10 mL). Work-up pro-
cedure A was used. Purification by flash column chromatography
(10 → 20% EtOAc/pentane) and trituration with MeOH afforded 18a
(106 mg, 51%) as a white solid. 1H NMR (acetone‑d6) δ 7.81 (d,
J = 2.2 Hz, 1H), 7.69 (d, J = 2.2 Hz, 1H), 6.62 (d, J = 12.2 Hz, 1H),
5.79 (s, 1H), 5.02–4.88 (m, 1H), 2.16–2.06 (m, 1H), 2.02–1.89 (m, 1H),
1.70–1.48 (m, 2H), 1.43–1.31 (m, 4H), 0.97–0.79 (m, 3H). 13C NMR
(acetone‑d6) δ 141.0, 138.7, 126.9, 126.0, 111.1, 108.6, 67.5, 34.6,
32.0, 25.0, 23.1, 14.2. Anal. (C12H16Br2N2O2S) C, H, N.
5,7-Dibromo-3-phenethyl-3,4-dihydro-2H-benzo[e][1,2,4]thia-
diazine-1,1-dioxide (18b). The compound was synthesized according
to the general procedure from 16 (200 mg, 0.61 mmol) and 17b
(0.08 mL, 0.50 mmol). Work-up procedure A was used. Purification by
flash column chromatography (10 → 20% EtOAc/pentane) and tri-
turation with MeOH afforded 18b (117 mg, 53%) as an white solid. 1H
NMR (DMSO‑d6) δ 8.02 (d, J = 11.4 Hz, 1H), 7.90 (d, J = 2.3 Hz, 1H),
7.67 (dd, J = 2.2, 0.6 Hz, 1H), 7.35–7.13 (m, 5H), 6.38 (s, 1H),
4.76–4.62 (m, 1H), 2.86–2.62 (m, 2H), 2.44–2.28 (m, 1H), 2.12–1.96
(m, 1H). 13C NMR (DMSO‑d6) δ 140.8, 140.2, 138.0, 128.4, 128.4,
126.0, 125.6, 124.3, 110.3, 107.3, 65.6, 34.5, 30.2. Anal.
(C15H14Br2N2O2S) C, H, N.
5,7-Dibromo-3-(3-bromophenethyl)-3,4-dihydro-2H-benzo[e]
[1,2,4]thiadiazine-1,1-dioxide (18c). The compound was synthesized
according to the general procedure from 16 (89 mg, 0.27 mmol) and
17c (63 mg, 0.29 mmol) in a microwave reactor at 120 °C for 1.5 h.
Work-up procedure A was used. Purification by flash column chroma-
tography (20 → 100% EtOAc/pentane) and recrystallization from
MeCN afforded 18c (52 mg, 34%) as an off-white solid. 1H NMR
(DMSO‑d6) δ 8.02 (d, J = 11.5 Hz, 1H), 7.91 (d, J = 2.2 Hz, 1H), 7.69
(dd, J = 2.3, 0.6 Hz, 1H), 7.51–7.46 (m, 1H), 7.43–7.36 (m, 1H),
7.31–7.23 (m, 2H), 6.40 (s, 1H), 4.77–4.64 (m, 1H), 2.90–2.60 (m, 2H),
2.45–2.27 (m, 1H), 2.13–1.95 (m, 1H). 13C NMR (DMSO‑d6) δ 143.7,
140.2, 138.0, 131.1, 130.5, 129.0, 127.6, 125.6, 124.3, 121.7, 110.3,
107.3, 65.5, 34.2, 29.7. Anal. (C15H13Br3N2O2S) C, H, N.
5,7-Dibromo-3-(2-(quinolin-2(1H)-one-6-yl)ethyl)-3,4-dihydro-
2H-benzo[e][1,2,4]thiadiazine-1,1-dioxide (18d). The compound
was synthesized according to the general procedure from 16 (75 mg,
0.23 mmol) and 17d (42 mg, 0.21 mmol). Work-up procedure B was
used and 18d (39 mg, 37%) was afforded as a light-brown solid. 1H
NMR (DMSO‑d6) δ 11.69 (s, 1H), 8.04 (d, J = 11.5 Hz, 1H), 7.91 (d,
J = 2.2 Hz, 1H), 7.85 (d, J = 9.5 Hz, 1H), 7.69 (d, J = 2.2 Hz, 1H),
7.51 (d, J = 1.9 Hz, 1H), 7.40 (dd, J = 8.4, 1.9 Hz, 1H), 7.25 (d,
J = 8.4 Hz, 1H), 6.48 (d, J = 9.5 Hz, 1H), 6.37 (s, 1H), 4.77–4.66 (m,
1H), 2.92–2.68 (m, 2H), 2.46–2.32 (m, 1H), 2.16–2.01 (m, 1H). 13C
NMR (DMSO‑d6) δ 161.8, 140.2, 140.0, 137.9, 137.3, 134.1, 130.9,
127.0, 125.5, 124.3, 122.0, 119.1, 115.2, 110.3, 107.3, 65.5, 34.5,
29.5. HRMS (ESI) m/z calcd for C18H16Br2N3O3S [M + H]+ 511.9279,
found 511.9273.
4.10. General procedure for synthesis of unsaturated benzothiadiazine
derivatives 21a–c
A solution of carboxylic acid (1.3 equiv) and CDI (1.2–1.8 equiv) in
dry CH2Cl2 (0.4–0.7 M) was stirred at room temperature for 1.5–4 h.
Sulfonamide 16 (1 equiv) dissolved in dry CH2Cl2 (0.4–0.5 M) and
15–50 vol% DMF was added and the solution was heated to reflux for
21 h. The solvent was removed and the residue was dissolved in a large
quantity of EtOAc and washed with 0.1 M HCl (aq), sat. Na2CO3 (aq)
and brine, dried over MgSO4, filtered and concentrated under reduced
pressure. The crude product was dissolved in EtOH, Cs2CO3 (2 equiv)
was added and the mixture was heated in a microwave reactor at 120 °C
for 1.5 h The solvent was removed and 1 M HCl (aq) was added. The
formed precipitation was filtered off and washed with EtOAc.
5,7-Dibromo-3-phenethyl-4H-benzo[e][1,2,4]thiadiazine-1,1-di-
oxide (21a). The compound was synthesized according to the general
procedure from 16 (373 mg, 1.13 mmol). Purification by re-
crystallization from MeCN afforded 21a (120 mg, 21% over two steps)
as an off-white solid.
1H NMR (DMSO‑d6) δ 7.98 (d, J= 2.4 Hz, 1H), 7.74 (d, J= 2.3 Hz,
1H), 7.31–7.20 (m, 4H), 7.14 (tt, J = 5.9, 3.0 Hz, 1H), 2.96 (m, 2H),
2.76 (t, J = 7.9 Hz, 2H). 13C NMR (DMSO‑d6) δ 163.0, 162.8, 141.0,
137.4, 128.4, 128.3, 126.0, 124.8, 124.4, 115.4, 115.1, 39.5, 32.2.
HRMS (ESI) m/z calcd for C15H13Br2N2O2S [M + H]+ 442.9064, found
442.9053.
5,7-Dibromo-3-(3-bromophenethyl)-3,4-dihydro-2H-benzo[e]
[1,2,4]thiadiazine-1,1-dioxide (21b). The compound was synthesized
according to the general procedure from 16 (251 mg, 0.76 mmol).
Purification by recrystallization from MeCN afforded 21b (97 mg, 24%
over two steps) as an off-white solid. 1H NMR (DMSO‑d6) δ 10.89 (s,
1H), 8.30 (d, J = 2.1 Hz, 1H), 8.01 (d, J = 2.1 Hz, 1H), 7.52 (dd,
J = 2.2, 1.5 Hz, 1H), 7.40 (ddd, J = 7.5, 2.1, 1.5 Hz, 1H), 7.32–7.23
(m, 2H), 3.15–3.06 (m, 2H), 2.98–2.92 (m, 2H). 13C NMR (DMSO‑d6) δ
161.1, 142.9, 138.9, 132.7, 131.2, 130.5, 129.1, 127.6, 125.4, 123.7,
121.6, 117.7, 111.6, 36.3, 31.2. Anal. (C15H11Br3N2O2S) C, H, N.
5,7-Dibromo-3-(4-bromophenethyl)-3,4-dihydro-2H-benzo[e]
[1,2,4]thiadiazine-1,1-dioxide (21c). The compound was synthesized
according to the general procedure from 16 (253 mg, 0.77 mmol).
Purification by recrystallization from MeCN afforded 21c (146 mg, 37%
over two steps) as an off-white solid. 1H NMR (DMSO‑d6) δ 10.89 (s,
1H), 8.29 (d, J = 2.1 Hz, 1H), 8.01 (d, J = 2.1 Hz, 1H), 7.48 (d,
J = 8.4 Hz, 2H), 7.25 (d, J = 8.4 Hz, 2H), 3.14–3.05 (m, 2H),
2.99–2.90 (m, 2H). 13C NMR (DMSO‑d6) δ 161.1, 139.5, 138.9, 132.7,
131.2, 130.7, 125.4, 123.8, 119.3, 117.7, 111.6, 36.3, 31.0. Anal.
(C15H11Br3N2O2S) C, H, N.
4.11. 5-Bromo-2-methylbenzenesulfonyl chloride (23)
A solution of ClSO3H (7.00 mL, 103 mmol) in CH2Cl2 (12 mL) was
added dropwise to an ice-cold solution of 4-bromotoluene (2.61 g,
15 mmol) in CH2Cl2 (25 mL). The mixture was stirred in an ice-bath
overnight, while the temperature increased to 10 °C. The solvent was
removed and the residue was added dropwise to ice-water. The formed
solid was filtered off and washed with water to afford a mixture (3.85 g,
94%, 86:14 ratio according to 1H NMR) of 23 (major isomer, 81%) and
2-bromo-5-methylbenzenesulfonyl chloride as a colourless oil. 1H NMR
(23) δ 8.20 (d, J = 2.1 Hz, 1H), 7.72 (dd, J = 8.2, 2.0 Hz, 1H), 7.31
(dd, J = 8.2, 0.8 Hz, 1H), 2.74 (s, 3H). 13C NMR (23) δ 144.1, 138.2,
137.0, 135.0, 131.4, 120.1, 20.0.
4.12. 5-Bromo-2-methylbenzenesulfonamide (24)
To an ice cold solution of 23 (5.83 g, 21.6 mmol) in Et2O (100 mL)
was added aqueous ammonia (25%, 20 mL). The mixture was refluxed
for 2 h and finally stirred at room temperature for 48 h. The solvent was
removed under reduced pressure and the formed solid was filtered off,
extensively washed with water and dried in vacuo to afford a mixture
(5.29 g, 98%, 83:17 ratio according to 1H NMR signal of CH3-group) of
24 (major isomer, 81%) and 2-bromo-5-methylbenzenesulfonamide
(minor isomer, 17%) as a white solid. 1H NMR (CD3OD, 24) δ 8.07 (d,
J = 2.1 Hz, 1H), 7.61 (dd, J = 8.2, 2.2 Hz, 1H), 7.28 (d, J = 8.1 Hz,
1H), 2.61 (s, 3H). 13C NMR (CD3OD, 25) δ 144.0, 135.3, 134.4, 134.4,
129.3, 118.4, 19.3.
4.13. 6-Bromosaccharin (28) synthesized from 24
To a mixture of H5IO6 (27.7 g, 122 mmol) and CrO3 (304 mg,
3.0 mmol) in MeCN (150 mL) was added 24 (3.80 g, 15.2 mmol, isomer
ratio 82:18) and the mixture was heated to reflux for 20 h. Isopropanol
(15 mL) was added and the mixture was heated to reflux for additional
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10 min. The mixture was allowed to cool to room temperature and the
formed solid was filtered off, rinsed with acetone and the filtrate was
concentrated under reduced pressure. The green coloured crude solid
was triturated with 1 M H2SO4 (aq, 15 mL) and the solid material was
filtered off, washed with water and pentane and dried in vacuo to afford
28 (1.60 g, 38% based on 24) as a white solid. 1H NMR (DMSO‑d6) δ
8.51 (d, J = 1.7 Hz, 1H), 8.09 (dd, J = 8.2, 1.7 Hz, 1H), 7.87 (d,
J = 8.1 Hz, 1H). 13C NMR (DMSO‑d6) δ 160.9, 141.5, 137.4, 128.7,
127.5, 126.4, 124.1.
4.14. 6-Bromosaccharin (28) synthesized from 23
A solution of 23 (7.06 g, 26.2 mmol) in dry CH2Cl2 (60 mL) was
dropwise added to a solution of tert-butylamine (2.88 mL, 27.5 mmol)
and Et3N (3.83 mL, 27.5 mmol) in CH2Cl2 (120 mL) at 0 °C. The mixture
was stirred at 0 °C for 1.5 h, was then allowed to warm to room tem-
perature and stirred at this temperature for 24 h. The mixture was
washed with 0.1 M HCl (aq.) and sat. NaHCO3 (aq.), dried over MgSO4,
filtered and concentrated under reduced pressure. The crude product
was purified by flash column chromatography (17% EtOAc/pentane) to
afford 25 (5.65 g, 70% yield, 23% of the other regioisomer). H5IO6
(15.5 g, 68.0 mmol) was vigorously stirred in MeCN (85 mL) for 1 h.
CrO3 (254 mg, 2.55 mmol) and acetic anhydride (6.4 mL, 68.0 mmol)
were added and the suspension was stirred for 10 min at room tem-
perature. The mixture was cooled in an ice-bath and 25 (2.60 g,
8.49 mmol, ratio 77:23 according to 1H NMR spectra) was added in
one portion. The mixture was stirred at 0 °C for 15 min and then al-
lowed to warm to room temperature and stirred for 13 h. The solvent
was removed and the remaining slurry was stirred in EtOAc (100 mL)
for 10 min. The solid was filtered off, washed with EtOAc and acetone
and the filtrate was concentrated under reduced pressure. Water was
added and the aqueous phase was extracted with EtOAc. The combined
organic phases were washed with sat. NaHCO3 (aq), sat. Na2S2O3 (aq)
and brine, dried over MgSO4, filtered and concentrated under reduced
pressure. The crude product was dissolved in TFA (20 mL) and heated
to reflux for 48 h and thereafter stirred at room temperature for 4 d. The
TFA was removed from the formed precipitate and concentrated under
reduced pressure. The precipitate and the remaining solid after eva-
poration were treated with CH2Cl2, and dried in vacuo to afford 28
(1.14 g, 62% overall yield based on 25). 1H NMR (CD3OD) δ 8.25 (d,
J = 1.6 Hz, 1H), 8.07 (dd, J = 8.1, 1.6 Hz, 1H), 7.91 (d, J = 8.2 Hz,
1H). 13C NMR (DMSO‑d6) δ 160.9, 141.5, 137.4, 128.7, 127.59, 126.4,
124.1.
4.15. General procedure for the synthesis of the sodium salt of saccharins
(29 and 30)
To a 0.2 M solution of saccharin (1 equiv) in dry MeOH, NaOMe
(1.01 equiv) was added and the mixture was stirred for 6 h at room
temperature. The solvent was removed and the residue was dried in
vacuo.
Sodium saccharin (29). The compound was synthesized according
to the general procedure from saccharin 27 (8.0 g, 44 mmol) to afford
29 (8.8 g, 98%) as a white solid which was directly used in the next
step.
Sodium 6-bromosaccharin (30). The compound was synthesized
according to the general procedure from 28 (824 mg, 2.97 mmol) to
afford 30 (896 mg,> 99%) as a white solid which was directly used in
the next step.
4.16. General procedure for the alkyl substituted saccharins 31a–d and
32a–f
The sodium salts of saccharin 29 or 30 (1 equiv) was dissolved in
DMF (1 M) and the appropriate halide (1.05 equiv) was added. The
mixture was heated in a microwave reactor at 145 °C for 1 h if not
otherwise stated. The mixture was poured on ice-water and the pre-
cipitate was filtered off, washed with water and pentane and dried in
vacuo. If no precipitate was formed, the aqueous phase was extracted
with EtOAc and the combined organic phases were washed with brine,
dried over MgSO4, filtered and concentrated under reduced pressure.
2-Pentylbenzo[d]isothiazol-3(2H)-one-1,1-dioxide (31a). The
compound was synthesized according to the general procedure from 29
(150 mg, 0.731 mmol). Purification by flash column chromatography
(40% EtOAc/pentane) afforded 31a (143 mg, 77%) as a colourless oil.
1H NMR δ 8.08–8.02 (m, 1H), 7.93–7.89 (m, 1H), 7.89–7.78 (m, 2H),
3.76 (t, J= 7.6 Hz, 2H), 1.92–1.78 (m, 2H), 1.44–1.32 (m, 4H), 0.91 (t,
J = 6.9 Hz, 3H). 13C NMR δ 159.1, 137.9, 134.8, 134.4, 127.6, 125.2,
121.0, 39.6, 29.0, 28.2, 22.3, 14.0. Anal. (C12H15NO3S) C, H, N.
2-Phenethylbenzo[d]isothiazol-3(2H)-one-1,1-dioxide (31b). The
compound was synthesized according to the general procedure from 29
(200 mg, 0.97 mmol). Purification by flash column chromatography
(30% EtOAc/pentane) afforded 31b (197 mg, 67%) as a white solid. 1H
NMR DMSO‑d6) δ 8.30 (ddd, J = 7.6, 0.9, 0.9 Hz, 1H), 8.09–7.94 (m,
3H), 7.34–7.15 (m, 5H), 3.99–3.88 (m, 2H), 3.09–2.97 (m, 2H). 13C
NMR (DMSO‑d6) δ 158.2, 137.6, 136.7, 135.8, 135.3, 128.7, 128.4,
126.6, 126.2, 125.0, 121.5, 39.8, 33.9. Anal. (C15H13NO3S) C, H, N.
Ethyl 4-(1,1-dioxo-3-oxobenzo[d]isothiazol-2(3H)-yl)butanoate
(31c). The compound was synthesized according to the general pro-
cedure from 29 (100 mg, 0.49 mmol) in a microwave reactor at 145 °C
for 15 min. Purification by flash chromatography (25% EtOAc/pentane)
afforded 31c (111 mg, 73%) as a colourless oil. 1H NMR δ 8.08–8.04
(m, 1H), 7.95–7.90 (m, 1H), 7.90–7.80 (m, 2H), 4.16 (q, J = 7.1 Hz,
2H), 3.86 (t, J = 7.0 Hz, 2H), 2.45 (t, J = 7.3 Hz, 2H), 2.18 (p,
J = 7.2 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR δ 172.5, 159.2,
137.8, 134.9, 134.5, 127.5, 125.3, 121.1, 60.7, 38.7, 31.4, 23.8, 14.4.
Anal. (C13H15NO5S) C, H, N.
2-(3-(Pyridin-3-yl)propyl)benzo[d]isothiazol-3(2H)-one-1,1-di-
oxide (31d). The compound was synthesized according to the general
procedure from 29 (88 mg, 0.43 mmol). Purification by flash column
chromatography (30 → 80% EtOAc/pentane) afforded 31d (15 mg,
12%) as a yellow oil.
1H NMR δ 8.49 (d, J = 1.6 Hz, 1H), 8.45 (dd, J = 4.8, 1.6 Hz, 1H),
8.10–8.03 (m, 1H), 7.95–7.91 (m, 1H), 7.90–7.80 (m, 2H), 7.55 (ddd,
J = 7.8, 2.3, 1.6 Hz, 1H), 7.22 (ddd, J = 7.8, 4.8, 0.9 Hz, 1H), 3.84 (t,
J = 7.2 Hz, 2H), 2.83–2.68 (m, 2H), 2.24–2.13 (m, 2H). 13C NMR δ
159.1, 150.1, 147.9, 137.8, 136.1, 135.9, 135.0, 134.5, 127.4, 125.3,
123.5, 121.1, 39.0, 30.3, 29.8. HRMS (ESI) m/z calcd for C15H15N2O3S
[M + H]+ 303.0803, found 303.0776.
6-Bromo-2-pentylbenzo[d]isothiazol-3(2H)-one-1,1-dioxide
(32a). The compound was synthesized according to the general pro-
cedure from 30 (100 mg, 0.33 mmol) in a microwave reactor at 145 °C
for 30 min. to afford 32a (67 mg, 58%) as an off-white solid. 1H NMR δ
8.05 (dd, J= 1.6, 0.6 Hz, 1H), 7.95 (dd, J= 8.1, 1.6 Hz, 1H), 7.90 (dd,
J = 8.2, 0.6 Hz, 1H), 3.79–3.71 (m, 2H), 1.84 (p, J = 7.5 Hz, 2H),
1.58–1.47 (m, 2H), 1.44–1.34 (m, 4H), 1.00–0.84 (m, 3H). 13C NMR δ
158.3, 139.2, 137.7, 129.8, 126.5, 126.3, 124.3, 39.8, 29.0, 28.2, 22.3,
14.0. HRMS (ESI) m/z calcd for C12H14BrNO3S [M]+ 330.9878, found
330.9877.
6-Bromo-2-phenethylbenzo[d]isothiazol-3(2H)-one-1,1-dioxide
(32b). The compound was synthesized according to the general pro-
cedure from 30 (150 mg, 0.50 mmol). Purification by recrystallization
from EtOAc/pentane afforded 32b (148 mg, 77%) as a white solid. 1H
NMR δ 8.08–8.04 (m, 1H), 7.95–7.90 (m, 1H), 7.90–7.80 (m, 2H), 4.16
(q, J = 7.1 Hz, 2H), 3.86 (t, J = 7.0 Hz, 2H), 2.45 (t, J = 7.3 Hz, 2H),
2.18 (p, J = 7.2 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR δ 158.1,
139.2, 137.8, 137.4, 129.9, 129.0, 128.8, 127.1, 126.6, 126.2, 124.3,
40.8, 34.8. Anal (C15H12BrNO3S) C, H, N.
6-Bromo-2-(4-hydroxyphenethyl)benzo[d]isothiazol-3(2H)-one-
1,1-dioxide (32c). The compound was synthesized according to the
general procedure from 30 (124 mg, 0.41 mmol). Purification by re-
crystallization from EtOAc/pentane afforded 32c (108 mg, 66%) as a
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white solid. 1H NMR (DMSO‑d6) δ 9.22 (s, 1H), 8.74 (d, J = 1.6 Hz,
1H), 8.17 (dd, J = 8.2, 1.7 Hz, 1H), 7.96 (d, J = 8.2 Hz, 1H), 7.06 (d,
J = 8.4 Hz, 2H), 6.67 (d, J = 8.4 Hz, 2H), 3.86 (dd, J = 8.4, 6.8 Hz,
2H), 2.91 (dd, J = 8.5, 6.7 Hz, 2H). 13C NMR (DMSO‑d6) δ 157.6,
156.0, 138.3, 138.2, 129.7, 129.4, 127.6, 126.8, 125.4, 124.7, 115.3,
40.3, 33.1. Anal. (C15H12BrNO4S) C, H, N.
6-Bromo-2-(3-bromophenethyl)benzo[d]isothiazol-3(2H)-one-
1,1-dioxide (32d). The compound was synthesized according to the
general procedure from 30 (114 mg, 0.38 mmol) to afford 32d (133 mg,
76%) as a white solid. 1H NMR δ 8.06 (dd, J = 1.6, 0.5 Hz, 1H), 7.96
(dd, J= 8.2, 1.6 Hz, 1H), 7.89 (dd, J= 8.2, 0.5 Hz, 1H), 7.47–7.43 (m,
1H), 7.39 (dt, J = 7.5, 1.7 Hz, 1H), 7.25–7.16 (m, 2H), 4.01–3.93 (m,
1H), 3.14–3.06 (m, 2H). 13C NMR δ 158.1, 139.6, 139.1, 137.9, 132.1,
130.4, 130.3, 130.1, 127.7, 126.7, 126.1, 124.4, 122.8, 40.4, 34.4.
Anal. (C15H11Br2NO3S) C, H, N.
6-Bromo-2-(3-nitrophenethyl)benzo[d]isothiazol-3(2H)-one-1,1-
dioxide (32e). The compound was synthesized according to the general
procedure from 30 (150 mg, 0.53 mmol) to afford 32e (166 mg, 76%)
as an off-white solid. 1H NMR (DMSO‑d6) δ 8.74 (dd, J = 1.7, 0.5 Hz,
1H), 8.20–8.15 (m, 2H), 8.08 (ddd, J = 8.2, 2.4, 1.0 Hz, 1H), 7.95 (dd,
J = 8.2, 0.5 Hz, 1H), 7.74 (ddd, J = 7.6, 1.7, 1.0 Hz, 1H), 7.58 (ddd,
J = 8.1, 7.6, 0.4 Hz, 1H), 4.05 (t, J = 7.0 Hz, 1H), 3.19 (t, J = 6.9 Hz,
1H). 13C NMR (DMSO‑d6) δ 157.8, 147.8, 140.1, 138.3, 138.1, 135.9,
129.9, 129.5, 126.8, 125.3, 124.8, 123.7, 121.7, 39.41, 33.2. Anal.
(C15H11BrN2O5S) C, H, N.
6-Bromo-2-(2-(1-succinimidyl)ethyl)benzo[d]isothiazol-3(2H)-
one-1,1-dioxide (32f). The compound was synthesized according to
the general procedure from 30 (90 mg, 0.3 mmol). Purification by re-
crystallization from EtOAc/pentane afforded 32f (71 mg, 59%) as a
white solid.
1H NMR (DMSO‑d6) δ 8.74 (dd, J = 1.7, 0.5 Hz, 1H), 8.20 (dd,
J= 8.2, 1.7 Hz, 1H), 8.02 (dd, J= 8.2, 0.5 Hz, 1H), 3.91–3.80 (m, 2H),
3.80–3.70 (m, 2H), 2.55 (s, 4H). 13C NMR (DMSO‑d6) δ 177.8, 157.9,
138.4, 137.9, 129.6, 126.8, 125.3, 125.0, 37.0, 35.6, 28.0. Anal.
(C13H11BrN2O5S) C, H, N.
4.17. SIRT1–3 in vitro assay
The Fluor de Lys fluorescence assays were based on the method
described in the BioMol product sheet (Enzo Life Sciences) using the
BioMol KI177 substrate for SIRT1 and the KI179 substrate for SIRT2
and SIRT3. The determined Km value of SIRT1 for KI177 was 58 μM,
and the Km of SIRT2 for KI179 was 198 μM.26 The Km of SIRT3 for
KI179 was reported by Enzo Life Sciences to be 32 μM. The Km values of
SIRT1, SIRT2 and SIRT3 for NAD+ were reported by BioMol to be
558 μM, 547 μM and 2 mM, respectively.
Briefly, assays were carried out using the Fluor de Lys acetylated
peptide substrate at 0.7 Km and NAD+ (Sigma N6522 or BioMol KI282)
at 0.9 Km, recombinant GST-SIRT1/2-enzyme or recombinant His-
SIRT3 and SIRT assay buffer (KI286). GST-SIRT1 and GST-SIRT2 were
produced as described previously.27,28 His-SIRT3 (BML-SE270) was
purchased from Enzo Life Sciences. The buffer, Fluor de Lys acetylated
peptide substrate, NAD+ and DMSO/compounds in DMSO (2.5 μL in
50 μL total reaction volume; DMSO from Sigma, D2650) were pre-
incubated for 5 min at room temperature. The reaction was started by
adding the enzyme. The reaction mixture was incubated for one hour at
37 °C. After that, Fluor de Lys developer (KI176) and 2 mM nicotina-
mide (KI283) in SIRT assay buffer (total volume 50 μL) were added, and
the incubation was continued for 45 min at 37 °C. Fluorescence read-
ings were obtained using EnVision 2104 Multilabel Reader (Perki-
nElmer) with excitation wavelength 370 nm and emission 460 nm.
4.18. Molecular modeling
4.18.1. Docking
The previously published 3D-structure of SIRT22 was prepared
using Protein Preparation Wizard29 implemented in the Schrödinger
Suite. Ensembles of conformations for each ligand to be docked were
generated in order to prevent the starting conformation bias the final
docking solutions. In case of a chiral compound, both enantiomers were
docked. The docking was conducted using Glide XP (extra precision)
into the proposed binding site for the chroman-4-one inhibitors.2 In the
docking trial the protein structure was held rigid while the ligands were
flexible. The best scored docking solutions that fulfilled the inhibitor-
enzyme key interactions were reported. Single point energies for each
docked ligand conformation were calculated, to be able to determine
their relative energies. All calculations have been performed using
OPLS3 force field21 in a water solvation model with tools implemented
in Schrödinger Suite.22
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